The Amine Content of PEGylated Chitosan Bombyx mori Nanoparticles Acts as a Trigger for Protein Delivery

In modern medicine, effective protein therapy is a major challenge to which a significant contribution can be expected from nanoscience through the development of novel delivery systems. Here we present the effect of the amine content of nanoparticles based on PEGylated chitosan Bombyx mori (PEG-O-ChsBm) copolymers on the entrapment of molecules in a search for highly efficient,nanocarriers. PEG-O-ChsBm copolymers were synthesized with amine contents from 1.12% to 0.70%, and nanoparticles were generated by self-assembly in dilute aqueous solutions. These nanoparticles successfully entrapped molecules with a wide range of sizes, the efficiency of which was dependent on their amine contents. While hydrophobic molecules were entrapped with high efficiency in all types of nanoparticle, hydrophilic molecules were entrapped only in those with low amine content. Bovine serum albumin, selected as a model protein, was entrapped in nanoparticles and efficiently released in acidic conditions. The triggered entrapment of molecules in PEG-O-ChsBm nanoparticles by selection of the appropriate amine content represents a straightforward way to modulate their delivery by fine changes in the properties of nanocarriers

The Amine Content of PEGylated Chitosan <i>Bombyx mori</i> Nanoparticles Acts as a Trigger for Protein Delivery

In modern medicine, effective protein therapy is a major challenge to which a significant contribution can be expected from nanoscience through the development of novel delivery systems. Here we present the effect of the amine content of nanoparticles based on PEGylated chitosan <i>Bombyx mori</i> (PEG-O-ChsBm) copolymers on the entrapment of molecules in a search for highly efficient nanocarriers. PEG-O-ChsBm copolymers were synthesized with amine contents from 1.12% to 0.70%, and nanoparticles were generated by self-assembly in dilute aqueous solutions. These nanoparticles successfully entrapped molecules with a wide range of sizes, the efficiency of which was dependent on their amine contents. While hydrophobic molecules were entrapped with high efficiency in all types of nanoparticle, hydrophilic molecules were entrapped only in those with low amine content. Bovine serum albumin, selected as a model protein, was entrapped in nanoparticles and efficiently released in acidic conditions. The triggered entrapment of molecules in PEG-O-ChsBm nanoparticles by selection of the appropriate amine content represents a straightforward way to modulate their delivery by fine changes in the properties of nanocarriers

The Amine Content of PEGylated Chitosan <i>Bombyx mori</i> Nanoparticles Acts as a Trigger for Protein Delivery

In modern medicine, effective protein therapy is a major challenge to which a significant contribution can be expected from nanoscience through the development of novel delivery systems. Here we present the effect of the amine content of nanoparticles based on PEGylated chitosan <i>Bombyx mori</i> (PEG-O-ChsBm) copolymers on the entrapment of molecules in a search for highly efficient nanocarriers. PEG-O-ChsBm copolymers were synthesized with amine contents from 1.12% to 0.70%, and nanoparticles were generated by self-assembly in dilute aqueous solutions. These nanoparticles successfully entrapped molecules with a wide range of sizes, the efficiency of which was dependent on their amine contents. While hydrophobic molecules were entrapped with high efficiency in all types of nanoparticle, hydrophilic molecules were entrapped only in those with low amine content. Bovine serum albumin, selected as a model protein, was entrapped in nanoparticles and efficiently released in acidic conditions. The triggered entrapment of molecules in PEG-O-ChsBm nanoparticles by selection of the appropriate amine content represents a straightforward way to modulate their delivery by fine changes in the properties of nanocarriers

Venous Thromboembolism Risk and Prophylaxis in the Acute Care Hospital Setting (ENDORSE Survey) Findings in Surgical Patients

Objective: To evaluate venous thromboembolism (VTE) risk in patients who underwent a major operation, including the use of, and factors influencing, American College of Chest Physicians-recommended types of VTE prophylaxis

Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients The ENDORSE Global Survey

Limited data are available regarding the risk for venous thromboembolism (VIE) and VIE prophylaxis use in hospitalised medically ill patients. We analysed data from the global ENDORSE survey to evaluate VTE risk and prophylaxis use in this population according to diagnosis, baseline characteristics, and country. Data on patient characteristics, VIE risk, and prophylaxis use were abstracted from hospital charts. VTE risk and prophylaxis use were evaluated according to the 2004 American College of Chest Physicians (ACCP) guidelines. Multivariable analysis was performed to identify factors associated with use of ACCP-recommended prophylaxis. Data were evaluated for 37,356 hospitalised medical patients across 32 countries. VIE risk varied according to medical diagnosis, from 31.2% of patients with gastrointestinal/hepatobiliary diseases to 100% of patients with acute heart failure, active noninfectious respiratory disease, or pulmonary infection (global rate, 41.5%). Among those at risk for VTE, ACCP-recommended prophylaxis was used in 24.4% haemorrhagic stroke patients and 40-45% of cardiopulmonary disease patients (global rate, 39.5%). Large differences in prophylaxis use were observed among countries. Markers of disease severity, including central venous catheters, mechanical ventilation, and admission to intensive care units, were strongly associated with use of ACCP-recommended prophylaxis. In conclusion, VIE risk varies according to medical diagnosis. Less than 40% of at-risk hospitalised medical patients receive ACCP-recommended prophylaxis. Prophylaxis use appears to be associated with disease severity rather than medical diagnosis. These data support the necessity to improve implementation of available guidelines for evaluating VIE risk and providing prophylaxis to hospitalised medical patients